08:00 , Feb 22, 2016 |  BC Week In Review  |  Company News

Rockwell Medical, Shanghai Fosun Pharmaceutical deal

Rockwell granted Fosun’s Wanbang Biopharmaceutical Co. Ltd. subsidiary exclusive, Chinese commercialization rights to Triferic ferric pyrophosphate citrate and calcitriol. Rockwell is eligible to receive up to $39 million in an upfront payment and milestones, plus...
01:15 , Feb 17, 2016 |  BC Extra  |  Company News

Rockwell partners Triferic in China

Rockwell Medical Inc. (NASDAQ:RMTI) granted the Wanbang Biopharmaceutical Co. Ltd. subsidiary of Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196) exclusive Chinese rights to commercialize Rockwell's Triferic ferric pyrophosphate citrate and calcitriol. Rockwell will receive...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Clinical News

RenaGel phosphate binder data

GELX announced positive results of a second Phase III trial of RenaGel to control elevated serum phosphorus levels in chronic kidney failure patients. The study, which included 82 dialysis patients with chronic kidney failure, began...
08:00 , Nov 5, 2012 |  BC Week In Review  |  Clinical News

Natpara: Phase III data

The double-blind, U.S. Phase III RELAY trial in 46 patients showed that 18% of patients receiving 25 µg Natpara and 25% of patients receiving 50 µg Natpara achieved the primary endpoint of a reduction in...
07:00 , Jul 30, 2012 |  BC Week In Review  |  Clinical News

BPM 31543: Phase I started

Berg Pharma began an open-label, U.S. Phase I trial to evaluate BPM 31543 applied to the scalp twice daily in about 18 patients with metastatic breast cancer who are receiving paclitaxel. Patients will receive BPM...
07:00 , Sep 26, 2011 |  BC Week In Review  |  Clinical News

Preotact endocrine/metabolic data

Data from an investigator-initiated trial in 18 patients with hypoparathyroidism showed that 100 µg NPSP558 given once every other day significantly reduced supplemental calcium requirements by 36% from baseline to 48 months (p<0.01). Additionally, 3...
07:00 , Sep 3, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Not applicable Studies in cell culture identified calcitriol derivatives that could be useful for treating cancer. In human breast cancer cells, the calcitriol derivatives...
07:00 , May 11, 2009 |  BC Week In Review  |  Clinical News

Vectical Ointment calcitriol autoimmune data

An international study in 324 patients showed that 53% and 64% of patients treated with Vectical reported a significant improvement in psoriasis symptoms from baseline to week 26 and 52, respectively. The affected body surface...
07:00 , Mar 16, 2009 |  BC Week In Review  |  Clinical News

Clobex clobetasol propionate autoimmune data

Galderma S.A. , Lausanne, Switzerland   Product: Clobex clobetasol propionate   Business: Autoimmune   Molecular target: Not available   Description: Topical formulation of 0.05% clobetasol propionate, a corticosteroid   Indication: Treat moderate to severe plaque...
07:00 , Mar 16, 2009 |  BC Week In Review  |  Clinical News

Vectical Ointment calcitriol autoimmune data

Interim data from 176 evaluable patients with moderate to severe plaque psoriasis showed that the sequential treatment of Clobex 0.05% clobetasol propionate spray for 4 weeks followed by 8 weeks of 3µ/g Vectical calcitriol was...